1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Adhesive Capsulitis (Frozen Shoulder) Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Adhesive Capsulitis (Frozen Shoulder) Treatment Market, by Treatment Type
8.1.1. Non-Surgical Treatments
8.1.1.1. Market Revenue and Forecast
8.1.2. Surgical Treatments
8.1.2.1. Market Revenue and Forecast
9.1. Adhesive Capsulitis (Frozen Shoulder) Treatment Market, by End-User
9.1.1. Hospitals
9.1.1.1. Market Revenue and Forecast
9.1.2. Clinics
9.1.2.1. Market Revenue and Forecast
9.1.3. Home Care Settings
9.1.3.1. Market Revenue and Forecast
9.1.4. Rehabilitation Centers
9.1.4.1. Market Revenue and Forecast
10.1. Adhesive Capsulitis (Frozen Shoulder) Treatment Market, by Therapy Type
10.1.1. Physical Therapy
10.1.1.1. Market Revenue and Forecast
10.1.2. Injection Therapy
10.1.2.1. Market Revenue and Forecast
10.1.3. Manual Therapy
10.1.3.1. Market Revenue and Forecast
11.1. Adhesive Capsulitis (Frozen Shoulder) Treatment Market, by Diagnosis
11.1.1. Clinical Diagnosis
11.1.1.1. Market Revenue and Forecast
11.1.2. Imaging Diagnosis
11.1.2.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Treatment Type
12.1.2. Market Revenue and Forecast, by End-User
12.1.3. Market Revenue and Forecast, by Therapy Type
12.1.4. Market Revenue and Forecast, by Diagnosis
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Treatment Type
12.1.5.2. Market Revenue and Forecast, by End-User
12.1.5.3. Market Revenue and Forecast, by Therapy Type
12.1.5.4. Market Revenue and Forecast, by Diagnosis
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Treatment Type
12.1.6.2. Market Revenue and Forecast, by End-User
12.1.6.3. Market Revenue and Forecast, by Therapy Type
12.1.6.4. Market Revenue and Forecast, by Diagnosis
12.2. Europe
12.2.1. Market Revenue and Forecast, by Treatment Type
12.2.2. Market Revenue and Forecast, by End-User
12.2.3. Market Revenue and Forecast, by Therapy Type
12.2.4. Market Revenue and Forecast, by Diagnosis
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Treatment Type
12.2.5.2. Market Revenue and Forecast, by End-User
12.2.5.3. Market Revenue and Forecast, by Therapy Type
12.2.5.4. Market Revenue and Forecast, by Diagnosis
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Treatment Type
12.2.6.2. Market Revenue and Forecast, by End-User
12.2.6.3. Market Revenue and Forecast, by Therapy Type
12.2.6.4. Market Revenue and Forecast, by Diagnosis
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Treatment Type
12.2.7.2. Market Revenue and Forecast, by End-User
12.2.7.3. Market Revenue and Forecast, by Therapy Type
12.2.7.4. Market Revenue and Forecast, by Diagnosis
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Treatment Type
12.2.8.2. Market Revenue and Forecast, by End-User
12.2.8.3. Market Revenue and Forecast, by Therapy Type
12.2.8.4. Market Revenue and Forecast, by Diagnosis
12.3. APAC
12.3.1. Market Revenue and Forecast, by Treatment Type
12.3.2. Market Revenue and Forecast, by End-User
12.3.3. Market Revenue and Forecast, by Therapy Type
12.3.4. Market Revenue and Forecast, by Diagnosis
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Treatment Type
12.3.5.2. Market Revenue and Forecast, by End-User
12.3.5.3. Market Revenue and Forecast, by Therapy Type
12.3.5.4. Market Revenue and Forecast, by Diagnosis
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Treatment Type
12.3.6.2. Market Revenue and Forecast, by End-User
12.3.6.3. Market Revenue and Forecast, by Therapy Type
12.3.6.4. Market Revenue and Forecast, by Diagnosis
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Treatment Type
12.3.7.2. Market Revenue and Forecast, by End-User
12.3.7.3. Market Revenue and Forecast, by Therapy Type
12.3.7.4. Market Revenue and Forecast, by Diagnosis
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Treatment Type
12.3.8.2. Market Revenue and Forecast, by End-User
12.3.8.3. Market Revenue and Forecast, by Therapy Type
12.3.8.4. Market Revenue and Forecast, by Diagnosis
12.4. MEA
12.4.1. Market Revenue and Forecast, by Treatment Type
12.4.2. Market Revenue and Forecast, by End-User
12.4.3. Market Revenue and Forecast, by Therapy Type
12.4.4. Market Revenue and Forecast, by Diagnosis
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Treatment Type
12.4.5.2. Market Revenue and Forecast, by End-User
12.4.5.3. Market Revenue and Forecast, by Therapy Type
12.4.5.4. Market Revenue and Forecast, by Diagnosis
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Treatment Type
12.4.6.2. Market Revenue and Forecast, by End-User
12.4.6.3. Market Revenue and Forecast, by Therapy Type
12.4.6.4. Market Revenue and Forecast, by Diagnosis
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Treatment Type
12.4.7.2. Market Revenue and Forecast, by End-User
12.4.7.3. Market Revenue and Forecast, by Therapy Type
12.4.7.4. Market Revenue and Forecast, by Diagnosis
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Treatment Type
12.4.8.2. Market Revenue and Forecast, by End-User
12.4.8.3. Market Revenue and Forecast, by Therapy Type
12.4.8.4. Market Revenue and Forecast, by Diagnosis
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Treatment Type
12.5.2. Market Revenue and Forecast, by End-User
12.5.3. Market Revenue and Forecast, by Therapy Type
12.5.4. Market Revenue and Forecast, by Diagnosis
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Treatment Type
12.5.5.2. Market Revenue and Forecast, by End-User
12.5.5.3. Market Revenue and Forecast, by Therapy Type
12.5.5.4. Market Revenue and Forecast, by Diagnosis
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Treatment Type
12.5.6.2. Market Revenue and Forecast, by End-User
12.5.6.3. Market Revenue and Forecast, by Therapy Type
12.5.6.4. Market Revenue and Forecast, by Diagnosis
13.1. Pfizer Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Sun Pharmaceutical Industries Ltd.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Dr. Reddy's Laboratories Ltd.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Cipla Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Eli Lilly and Company
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Merck & Co., Inc.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Johnson & Johnson
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Novartis AG
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Sanofi S.A.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. GlaxoSmithKline plc
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
